CHEK2 and renal cell carcinoma: While CHEK2 variation was originally identified as conferring a 2-fold increase in breast cancer risk (21), it is increasingly being recognized that variants predispose to other cancers, including colorectal (22) and prostate (23), and more recently has been linked to RCC with studies suggesting a lifetime risk of 2% (24–26).